2025-11-23 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the information you provided, formatted as a report.

**Report on TG Therapeutics (TGTX)**

**1. Performance Overview**

*   **Ticker:** TGTX
*   **Company Description:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **Cumulative Return (TGTX):** 79.54%
*   **Cumulative Return (S&P 500/VOO):** 94.64%
*   **Return Disparity:** -19.9 (Relative Disparity: 19.9).  This indicates that TGTX has underperformed the S&P 500.

**1.1. Alpha/Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | -5.0%   | 73.5%   | -33.0%  | 0.1   | 1.3    |
| 2016-2018  | -12.0%  | 73.5%   | -27.0%  | 0.0   | 0.7    |
| 2017-2019  | 74.0%   | 74.1%   | 52.0%   | 0.0   | 1.8    |
| 2018-2020  | 316.0%  | 74.1%   | 293.0%  | 0.1   | 8.3    |
| 2019-2021  | 124.0%  | 74.1%   | 78.0%   | 0.3   | 3.0    |
| 2020-2022  | -71.0%  | 77.8%   | -71.0%  | -0.0  | 1.9    |
| 2021-2023  | -284.0% | 77.8%   | -285.0% | -1.0  | 2.7    |
| 2022-2024  | 56.0%   | 77.8%   | 36.0%   | -1.0  | 4.8    |
| 2023-2025  | 80.0%   | 80.7%   | 21.0%   | -0.1  | 5.1    |

*   **Analysis:** This table shows rolling 3-year periods.
    *   **CAGR:**  Fluctuates significantly, indicating volatile performance.  Recent periods have shown negative returns.
    *   **MDD (Maximum Drawdown):**  Consistently high, indicating substantial risk of loss.
    *   **Alpha:**  Often negative, meaning TGTX has underperformed its benchmark (risk-adjusted).  There are periods of high positive alpha, but recent periods are very negative.
    *   **Beta:**  Generally low (close to 0 in many periods, negative in recent periods), suggesting a relatively low correlation with the overall market but recently turns to negative number
    *   **Cap(B):** Company value varies, growth is unstable
        *    **Conclusion:** TG Therapeutics has demonstrated unstable company growth. In addition, it seems that the volatility of the company has increased, as the degree of decline has increased due to market conditions.

**2. Recent Stock Performance**

*   **Current Price:** 31.95
*   **Previous Close:** 30.45
*   **Change:** 4.93%
*   **5-day Moving Average:** 30.926
*   **20-day Moving Average:** 32.3645
*   **60-day Moving Average:** 33.4247

*   **Analysis:** The price increased by 4.93% at the market's close. However, it is below both the 20-day and 60-day moving averages, suggesting a possible short-term downward trend.  The recent price increase could signal a potential reversal, but it's too early to confirm.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 39.67 (Approaching oversold territory, but not quite there)
*   **PPO:** -0.2495 (Slightly negative, indicating a short-term downtrend)
*   **Hybrid Signal:** cash_80%_Sell (Suggests a strategy of selling 80% of holdings due to risk)
*   **Recent (20-day) Relative Disparity Change:** -0.4 (Indicates recent underperformance relative to the benchmark)
*   **Expected Return:** -112.7% (This is a *very* negative outlook, suggesting significant underperformance relative to the S&P 500 over the long term if a dollar-cost averaging strategy is used.)

*   **Analysis:**
    *   The MRI indicates medium investment risk, but the Hybrid Signal is strongly bearish.
    *   The large price change (4.93%) suggests a reaction to recent news or events.
    *   The significantly negative expected return is a major red flag.

**4. Recent News & Significant Events**

*   **Positive:**
    *   TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List
    *   Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term (Zacks)
    *   TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
*   **Negative:**
    *   TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
    *   TG Therapeutics (TGTX) Margin Miss Challenges Growth-Driven Profitability Narrative (Simply Wall St.)
    *   TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

*   **Analysis:** Recent news is mixed. While recognition on the Deloitte Fast 500 and positive earnings reports provide some optimism, news about Roche's test results and margin concerns appear to be weighing on the stock.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.67 (~Buy)
*   **Opinions:** 7
*   **Target Price (avg/high/low):** 44.29 / 60.00 / 13.00
*   **Analysis:**  Analysts, on average, have a "Buy" rating and a target price significantly higher than the current price. However, the wide range in target prices (13.00 to 60.00) indicates uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-11-05 | 2.69 | 0.16 B$    |
| 2025-08-08 | 0.19 | 0.14 B$    |
| 2025-05-09 | 0.03 | 0.12 B$    |
| 2024-11-07 | 0.03 | 0.08 B$    |
| 2025-11-05 | 0.03 | 0.08 B$    |

*   **Analysis:** The most recent EPS is significantly higher than previous quarters. Revenue has generally been increasing. This suggests improved profitability in the most recent period.

**6. Financial Information**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.16B    | 82.63%        |
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |

| Quarter      | Equity    | ROE        |
|--------------|-----------|------------|
| 2025-09-30   | $0.61B    | 64.37%     |
| 2025-06-30   | $0.28B    | 10.20%     |
| 2025-03-31   | $0.24B    | 2.13%      |
| 2024-12-31   | $0.22B    | 10.49%     |
| 2024-09-30   | $0.19B    | 2.02%      |

*   **Analysis:**
    *   Revenue is steadily increasing.
    *   Profit margins are very high, suggesting strong pricing power or cost control.
    *   Equity has increased significantly in the most recent quarter.
    *   ROE is extremely high in the most recent quarter, likely related to the equity increase and strong earnings.

**7. Overall Analysis and Recommendation**

TG Therapeutics presents a mixed picture.

*   **Positives:**
    *   Strong revenue and profit margin growth.
    *   Positive analyst consensus (Buy rating).
    *   Recent EPS beat.
    *   Inclusion on the Deloitte Technology Fast 500 list.
*   **Negatives:**
    *   Historical underperformance relative to the S&P 500.
    *   High maximum drawdown, indicating significant risk.
    *   *Very* negative expected return (-112.7%).
    *   Bearish Hybrid Signal.
    *   Negative news regarding Roche's test results and margin concerns.

**Recommendation:**  Due to the significantly negative expected return and bearish Hybrid Signal, a *sell* or *hold* recommendation is warranted.  The recent positive earnings and revenue growth are encouraging, but the overall risk profile appears too high for a new investment.  Existing investors should carefully consider reducing their positions.  It's crucial to monitor the impact of Roche's test results and the company's ability to maintain its high profit margins. The recent 4.93% increase in stock price should be regarded carefully, as it could be just a temporary fluctuation.
